When to Suspect and Diagnose Intrahepatic Cholestasis of Pregnancy
Suspect intrahepatic cholestasis of pregnancy (ICP) in any woman presenting with new-onset pruritus without a rash in the second or third trimester, and confirm the diagnosis by measuring serum bile acids and liver transaminases 1.
Clinical Suspicion: When to Think ICP
Key Presenting Features
Suspect ICP when a pregnant woman presents with:
- Pruritus characteristics that distinguish ICP:
- Generalized itching that predominantly affects palms and soles
- Worse at night
- Absence of a primary rash (excoriations from scratching may be present)
- Onset typically in the second or third trimester 1
Critical Differential Diagnosis
Before confirming ICP, you must distinguish it from other causes of pruritus in pregnancy, which affects approximately 23% of all pregnancies 1. The most common pregnancy-specific pruritic conditions that do present with rashes include:
- Atopic eruption of pregnancy (AEP) - eczematous rash on face, neck, flexural areas
- Polymorphic eruption of pregnancy (PEP) - urticarial papules and plaques on abdomen and thighs
- Pemphigoid gestationis (PG) - vesicles and bullae
Non-pregnancy-specific causes of pruritus without rash to exclude include chronic renal failure, thyroid disorders, liver disease, HIV, lymphomas, and drug reactions 1.
Diagnostic Testing: Confirming ICP
Order serum bile acids and liver transaminases (ALT/AST) in all patients with suspected ICP 1. This is a GRADE 1B recommendation from SMFM, endorsed by ACOG.
Diagnostic Criteria
The diagnosis is confirmed by:
- Elevated total serum bile acids (TSBA) - the hallmark of ICP
- Elevated liver transaminases (ALT/AST) may or may not be present
- Pruritus in the appropriate clinical context
Important Diagnostic Nuances
A critical pitfall: Do not proceed with preterm delivery based on clinical symptoms alone without laboratory confirmation of elevated bile acids 1. The 2021 SMFM guidelines explicitly recommend against delivery before 37 weeks in patients with clinical suspicion but normal bile acid levels (GRADE 1B).
Recent evidence from the 2023 European Association for the Study of the Liver guidelines, validated in a large US cohort, stratifies patients into three groups 2:
- Group A: Normal TSBA and normal ALT/AST (not ICP)
- Group B: Elevated ALT/AST with normal TSBA (24% of suspected cases)
- Group C: Elevated TSBA ≥19 μmol/L with or without elevated ALT/AST (11% of suspected cases - true ICP)
This classification matters because both Groups B and C warrant antepartum surveillance, as Group B patients also show increased rates of preeclampsia and adverse outcomes, though Group C carries the highest risk for spontaneous preterm birth, meconium-stained fluid, and neonatal respiratory distress 2.
Why This Matters: The Fetal Risk
The urgency of diagnosis stems from significant fetal risks, not maternal ones. ICP poses little risk to the mother but carries substantial fetal risks including preterm delivery, meconium-stained amniotic fluid, and stillbirth 1. The risk of stillbirth increases substantially when total bile acid levels reach 100 μmol/L 1.
Common Pitfalls to Avoid
- Don't dismiss pruritus as "normal pregnancy discomfort" - any new-onset pruritus in the second or third trimester warrants bile acid testing
- Don't wait for abnormal liver enzymes - bile acids may be elevated before transaminases rise 3
- Don't act on symptoms alone - laboratory confirmation is essential before implementing management that includes preterm delivery 1
- Don't forget to exclude other causes - perform a thorough evaluation for non-pregnancy-related causes of pruritus and cholestasis 1